U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT03394885) titled 'Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer' on Nov. 29, 2017.
Brief Summary: The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.
Study Type: Interventional
Condition: * Ovarian Cancer
* Ovarian Neoplasms
Intervention: * Drug: Atezolizumab
1200mg IV q3weeks
Other Name: Tecentriq
* Drug: Carboplatin
5-6mg/ML IV q3 weeks
Other Name: Paraplatin
* D...